Zarębska-Michaluk, D.; Jaroszewicz, J.; Parfieniuk-Kowerda, A.; Pawłowska, M.; Janczewska, E.; Berak, H.; Janocha-Litwin, J.; Klapaczyński, J.; Tomasiewicz, K.; Piekarska, A.;
et al. Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection. J. Clin. Med. 2022, 11, 389.
https://doi.org/10.3390/jcm11020389
AMA Style
Zarębska-Michaluk D, Jaroszewicz J, Parfieniuk-Kowerda A, Pawłowska M, Janczewska E, Berak H, Janocha-Litwin J, Klapaczyński J, Tomasiewicz K, Piekarska A,
et al. Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection. Journal of Clinical Medicine. 2022; 11(2):389.
https://doi.org/10.3390/jcm11020389
Chicago/Turabian Style
Zarębska-Michaluk, Dorota, Jerzy Jaroszewicz, Anna Parfieniuk-Kowerda, Małgorzata Pawłowska, Ewa Janczewska, Hanna Berak, Justyna Janocha-Litwin, Jakub Klapaczyński, Krzysztof Tomasiewicz, Anna Piekarska,
and et al. 2022. "Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection" Journal of Clinical Medicine 11, no. 2: 389.
https://doi.org/10.3390/jcm11020389
APA Style
Zarębska-Michaluk, D., Jaroszewicz, J., Parfieniuk-Kowerda, A., Pawłowska, M., Janczewska, E., Berak, H., Janocha-Litwin, J., Klapaczyński, J., Tomasiewicz, K., Piekarska, A., Krygier, R., Citko, J., Tronina, O., Dobrowolska, K., & Flisiak, R.
(2022). Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection. Journal of Clinical Medicine, 11(2), 389.
https://doi.org/10.3390/jcm11020389
